Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer

NCT ID: NCT01998126

Last Updated: 2018-04-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 14 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-12-02
• Study Completion Date: 2018-03-29

Brief Summary

The goals of the overall study are to evaluate a recommended phase 2 dose and the short and long term toxicities of the combinations. This is a modified phase I trial of immune checkpoint inhibitors in combination with mutation - specific targeted therapy (crizotinib or erlotinib) at conventional doses stratified for presence of ALK (Anaplastic lymphoma kinase) or EGFR (epidermal growth factor receptor) mutation.

The goals of the overall study are to evaluate a recommended phase 2 dose and the short and long term toxicities of the combinations.

Conditions

Non-small Cell Lung Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

EGFR patients with ipilimumab

ipilimumab and erlotinib in EGFR mutated patients

Group Type: EXPERIMENTAL

Ipilimumab

Intervention Type: DRUG

Ipilimumab 3 mg/kg x 4 (given with standard Erlotinib or Crizotinib based on mutation)

Erlotinib

Intervention Type: DRUG

Erlotinib 150 mg once daily or current tolerable dose (given with Ipilimumab)

ALK patients plus ipilimumab

ipilimumab and crizotinib in ALK mutated patients

Group Type: EXPERIMENTAL

Ipilimumab

Intervention Type: DRUG

Ipilimumab 3 mg/kg x 4 (given with standard Erlotinib or Crizotinib based on mutation)

Crizotinib

Intervention Type: DRUG

Crizotinib 250 mg twice daily or current tolerable dose (given with Ipilimumab)

EGFR patients with nivolumab

nivolumab and erlotinib in EGFR mutated patients

Group Type: EXPERIMENTAL

Erlotinib

Intervention Type: DRUG

Erlotinib 150 mg once daily or current tolerable dose (given with Ipilimumab)

Nivolumab

Intervention Type: DRUG

ALK patients plus nivolumab

nivolumab and crizotinib in ALK mutated patients

Group Type: EXPERIMENTAL

Crizotinib

Intervention Type: DRUG

Crizotinib 250 mg twice daily or current tolerable dose (given with Ipilimumab)

Nivolumab

Intervention Type: DRUG

Interventions

Ipilimumab

Ipilimumab 3 mg/kg x 4 (given with standard Erlotinib or Crizotinib based on mutation)

Intervention Type: DRUG

Erlotinib

Erlotinib 150 mg once daily or current tolerable dose (given with Ipilimumab)

Intervention Type: DRUG

Crizotinib

Crizotinib 250 mg twice daily or current tolerable dose (given with Ipilimumab)

Intervention Type: DRUG

Nivolumab

Intervention Type: DRUG

Other Intervention Names

Yervoy; Nivolumab 240 mg every 2 weeks

Eligibility Criteria

Inclusion Criteria

• Diagnosis of Stage IV Non-Small Cell Lung Cancer (NSCLC), or Stages II - III NSCLC that cannot be treated curatively with standard techniques.
• Non-Small Cell Lung Cancer (NSCLC) that is either EGFR or ALK mutated.
• Untreated with/or actively treated with specific inhibitor for less than 6 months if not progressing on active therapy.
• Age > 18.
• ECOG performance status 0, 1 or 2.
• Prior chemotherapy is allowed if > one month from the end of treatment. Patients must not have received chemotherapy within 4 weeks of the start of study drug.
• Brain metastases are allowed if the patient is asymptomatic or previous steroid treatment was discontinued > 6 weeks.
• Adequate bone marrow function as defined in the protocol
• Serum bilirubin levels < 1.5 mg/dL except for patients with Gilbert's syndrome.
• Adequate organ function as defined in the protocol
• If female and of childbearing potential, documentation of negative pregnancy test (serum or urine) within 7 days prior to first dose.
• Able to provide informed consent and have signed an approved consent form that conforms to federal and institutional guidelines.

Exclusion Criteria

• Concurrent therapy with any other non-protocol anti-cancer therapy.
• History of any other malignancy requiring active treatment.
• Patients who have had a history of acute diverticulitis, intra-abdominal abscess, Gastrointestical obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation.
• History of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune vasculitis [e.g., Wegener's Granulomatosis]); motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre Syndrome). History of vitiligo and adequately controlled endocrine deficiencies such as hypothyroidism are allowed.
• Significant cardiovascular disease including:
• Active, clinically symptomatic left ventricular failure.
• Uncontrolled symptomatic hypertension that cannot be controlled with anti-hypertensive agents.
• Myocardial infarction, severe angina, or unstable angina within 6 months prior to administration of first dose of study drug.
• History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation)
• Cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with anti-arrhythmic medication)
• Coronary or peripheral artery bypass graft within 6 months of screening.
• Uncontrolled CNS metastases are not allowed; subjects with previously treated brain metastases will be allowed if the brain metastases have been treated, toxicities have resolved to grade 1 or baseline and steroids are no longer required. Leptomeningeal metastases are not allowed.
• Serious/active infection or infection requiring parenteral antibiotics.
• Pregnant or lactating females.
• HIV infection or chronic hepatitis B or C. Negative Screening tests for HIV, Hepatitis B, and Hepatitis C are required.
• The presence of any other medical or psychiatric disorder that, in the opinion of the treating physician, would contraindicate the use of the drugs in this protocol or place the subject at undue risk for treatment complications.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Bristol-Myers Squibb

INDUSTRY

Sponsor Role: collaborator

University of Utah

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Huntsman Cancer Institute

Salt Lake City, Utah, United States

Countries

United States

References

Chalmers AW, Patel S, Boucher K, Cannon L, Esplin M, Luckart J, Graves N, Van Duren T, Akerley W. Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up. Target Oncol. 2019 Aug;14(4):417-421. doi: 10.1007/s11523-019-00658-0.

Reference Type: DERIVED

PMID: 31346927 (View on PubMed)

Other Identifiers

HCI66705

Identifier Type: -

Identifier Source: org_study_id